Cover Image

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study

Abstract Background Incarcerated populations experience an elevated prevalence of opioid use disorder (OUD). Federal correctional institutions in Canada have increasingly treated OUD among correctional populations via opioid agonist treatment (OAT) - an evidence based pharmacotherapy that works to r...

Full description

Saved in:

Bibliographic Details
Main Authors:	Cayley Russell (Author), Frishta Nafeh (Author), Michelle Pang (Author), Shanna Farrell MacDonald (Author), Dena Derkzen (Author), Jürgen Rehm (Author), Benedikt Fischer (Author)
Format:	Book
Published:	BMC, 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Applying the socio-ecological model to understand community reintegration experiences among individuals on opioid agonist treatment (OAT) released from federal incarceration in Ontario, Canada
by: Cayley Russell, et al.
Published: (2022)

Youth substance use service provider's perspectives on use and service access in ontario: time to reframe the discourse
by: Farihah Ali, et al.
Published: (2022)

A qualitative examination of substance use service needs among people who use drugs (PWUD) with treatment and service experience in Ontario, Canada
by: Cayley Russell, et al.
Published: (2021)

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)
by: Scott Beaumont, et al.
Published: (2024)

Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
by: Eugenia Oviedo-Joekes, et al.
Published: (2023)

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC
by: Dobischok S, et al.
Published: (2023)

Erratum to: The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario
by: Alexandra M. Franklyn, et al.
Published: (2017)

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
by: Kristen A. Morin, et al.
Published: (2020)

The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data
by: Sameer Imtiaz, et al.
Published: (2021)

Recent changes in trends of opioid overdose deaths in North America
by: Sameer Imtiaz, et al.
Published: (2020)

Opioid Antagonists: Will they Solve all of the Problems Associated with Opioid Agonists?
by: Adam M Kaye
Published: (2014)

Examining correlations between opioid dispensing and opioid-related hospitalizations in Canada, 2007-2016
by: Wayne Jones, et al.
Published: (2020)

Interim opioid agonist treatment for opioid addiction: a systematic review
by: Laura Samsó Jofra, et al.
Published: (2022)

P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT)
by: J. Keats, et al.
Published: (2017)

Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada
by: Benedikt Fischer, et al.
Published: (2020)

Therapeutic Potential of Kappa Opioid Agonists
by: Tyler C. Beck, et al.
Published: (2019)

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
by: Kristen A. Morin, et al.
Published: (2019)

Network Analysis of Medical Claims Data Suggests Network-Based, Regional Targeting and Intervention Delivery Strategies to Increase Access to Office Based Opioid Treatment (OBOT) for Opioid Use Disorder (OUD)
by: Harold D. Green PhD, et al.
Published: (2024)

Medications for opioid use disorder during incarceration and post-release outcomes
by: Lara Cates, et al.
Published: (2023)

Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
by: Farah Tahsin, et al.
Published: (2022)

Correction to: Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
by: Kristen A. Morin, et al.
Published: (2019)

The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis?
by: Benedikt Fischer, et al.
Published: (2020)

Role for μ-opioid receptor in antidepressant effects of δ-opioid receptor agonist KNT-127
by: Yuki Moriya, et al.
Published: (2023)

'Safer opioid distribution' as an essential public health intervention for the opioid mortality crisis - Considerations, options and examples towards broad-based implementation
by: Benedikt Fischer, et al.
Published: (2020)

The continuous opioid death crisis in Canada: changing characteristics and implications for path options forward
by: Benedikt Fischer
Published: (2023)

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review
by: Michael Soyka
Published: (2021)

The opioid crisis: past, present and future policy climate in Ontario, Canada
by: Kristen A. Morin, et al.
Published: (2017)

The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study
by: Natasa Gisev, PhD, et al.
Published: (2019)

Opioid agonist treatment take-home doses ('carries'): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?
by: Cayley Russell, et al.
Published: (2022)

Food insecurity, chronic pain, and use of prescription opioids
by: Fei Men, et al.
Published: (2021)

μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
by: Leah M. Salinsky, et al.
Published: (2023)

Some notes on the use, concept and socio-political framing of 'stigma' focusing on an opioid-related public health crisis
by: Benedikt Fischer
Published: (2020)

Prescription opioid dispensing in Canada: an update on recent developments to 2018
by: Wayne Jones, et al.
Published: (2020)

Trends in dispensing of individual prescription opioid formulations, Canada 2005-2020
by: Wayne Jones, et al.
Published: (2022)

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment
by: Marchand Kirsten, et al.
Published: (2012)

Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
by: Anne Berit Bech, et al.
Published: (2019)

"Expected to happen": perspectives on post-release overdose from recently incarcerated people with opioid use disorder
by: Pryce S. Michener, et al.
Published: (2024)

Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment.
by: Daniel J Bromberg, et al.
Published: (2023)

Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment
by: Daniel J. Bromberg, et al.
Published: (2023)

Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013-2017): a prospective cohort study
by: Jørn Henrik Vold, et al.
Published: (2020)